News

Article

Clinical Quiz: Psoriasis Guidelines in Pediatric Patients

In this clinical quiz, you will test your knowledge of psoriasis guidelines, with special focus on important clinical questions related to management of psoriasis and recent evidence-based recommendations.

Psoriasis is a disease which is chronic, inflammatory, and impacts several systems of the body, affecting about 1% of children. In fact, most cases of psoriasis are initiated during adolescence.

The latest joint American Academy of Dermatology and National Psoriasis Foundation guideline was designed to deal with key clinical questions associated with management of psoriasis, providing recommendations based on current evidence.1 The guideline is aimed at pediatric psoriasis patients, considering their distinct pharmacokinetics, physiology, and the dynamics between caregivers, patients, and healthcare providers.

The managing of psoriasis and its extracutaneous symptoms in children and teenagers is the focus, with the recommendations covering treatment options such as topical and systemic therapies, and phototherapy, as well as addressing comorbidities such as psychosocial health and quality of life (QOL).

During this clinical quiz, you may test your awareness of the updated recommendations by the American Academy of Dermatology and National Psoriasis Foundation on this topic.

True or False: Psoriasis is a chronic, multisystem, inflammatory disease that affects approximately 1% of children.


Editor’s note: This quiz was generated through the use of AI tools.

References

  1. Menter A, Cordoro KM, Elmets CA, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020 Jan;82(1):161-201. doi: 10.1016/j.jaad.2019.08.049. Epub 2019 Nov 5. Erratum in: J Am Acad Dermatol. 2020 Mar;82(3):574. doi: 10.1016/j.jaad.2020.01.061. PMID: 31703821.
Related Videos
Implications of Findings on Patient-Reported Outcomes for Roflumilast Foam, with Melinda Gooderham, MD
New Findings on Psoriasis Outcomes for Roflumilast Foam 0.3%, with Melinda Gooderham, MD
Methods to Manage Psoriasis Using Oral Therapies, with Andrea Murina, MD
James Del Rosso, DO: Discussing What’s New in the Medicine Chest for Dermatologists
Melodie Young, ASN, RN: Updates on Therapies for Pediatric Patients with Psoriasis, PsA
Harnessing Patient Insights: The Role of PROs in Managing Psoriasis and Psoriatic Arthritis
Melinda Gooderham, MD: What Do the New Roflumilast Foam Data Mean for Psoriasis Patients?
Linda Stein Gold, MD, and Bruce Strober, MD, PhD
Linda Stein Gold, MD, and Bruce Strober, MD, PhD
Linda Stein Gold, MD, and Bruce Strober, MD, PhD
© 2024 MJH Life Sciences

All rights reserved.